妇炎净合剂治疗慢性盆腔炎的疗效评价及其对Ⅲ型胶原蛋白mRNA表达的影响
|
摘要
本课题在总结三十余年临床经验的基础上，立“逐瘀清化法”治疗慢性
盆腔炎，并创研妇炎净合剂。采用随机、对照法对妇炎净合剂治疗慢性盆腔
炎进行了临床疗效评价。使用L16(28) 表正交分析法对妇炎净合剂进行了拆
方分析，研究方中各药物的作用。经典方法对妇炎净合剂进行了一般药效学
及模型病理观察，观察了试验药对大鼠脾细胞、NIH3T3成纤维细胞增殖及Ⅲ
型胶原蛋白mRNA表达的影响，以探讨妇炎净合剂对脾细胞、成纤维细胞及
胶原转录基因的调节作用。通过以上实验研究，从整体、细胞、分子水平系
统分析了妇炎净合剂治疗慢性盆腔炎的机理。结果如下：
(1) 临床观察结果：采用随机、对照方法观察治疗180例慢性盆腔炎
患者，其中治疗组120例、对照组60例，结果显示，治疗组有效率96． 67％，
愈显率78． 33％，对照组有效率80％，愈显率34％，两组比较有显著性差异
(P＜0． 01) 。治疗组腹痛、腹坠胀、腰酸痛、带下主要症状的改善，优于对照
组，两组比较有显著性差异(P＜0． 01) 。
(2) 正交分析结果：采用L16(28) 正交表分析表明，妇炎净合剂方中
A、B、E、F、D药物是主要作用因素。
(3) 一般药效学研究结果：妇炎净合剂具有抑制二甲苯至小鼠耳肿胀，
抑制大鼠塑料环肉芽肿增生，减少小鼠冰醋酸所致扭体次数，提高大鼠痛阈，
降低小鼠冰醋酸所致腹腔毛细血管通透性的作用。
(4) MTT法检测显示：妇炎净合剂能抑制体外培养大鼠脾细胞、
NIH3T3成纤维细胞增生。RT-PCR方法检测结果：妇炎净合剂能抑制NIH3T3
成纤维细胞Ⅲ型胶原蛋白mRNA的表达。
结论妇炎净合剂是临床治疗慢性盆腔炎的有效药物。具有镇痛、减轻
渗出、减少局部增生、减轻盆腔病理改变的药理作用。深入研究表明，妇炎
净合剂可抑制成纤维细胞增生及其Ⅲ型胶原蛋白mRNA表达，分析该作用是
药物逆转慢性炎症局部病理改变的重要机制之一，体现了“逐瘀清化”法在
慢性盆腔炎治疗中的重要意义。
Objective: The subject systematicly treats chronic pelvic inflammatory disease (CPID) with "Zhu Yu Qing Hua" method based on better clinical effects in 30 years over, established "FU YAN JING" mixture. To observe and study clinical effects of chronic pelvic inflammatory disease (CPID) by Fu Yan Jing mixture, explore the mechanisms on improving chronic inflammatory pathology.
Method and Result: (1) In clinic, using method of random, contrast for observing and treating 180 cases of patients with chronic pelvic inflammatory disease (CPID), dividing them into 120 cases in treating group, 60 cases in controlling group. The results show that in total effects, there are totally effective rate 96.67% and cure rate and markedly effective rate 78.33%. Compared with control group, there is obvious differential (/><0.01). In the effects of clinical symptom such as abdominal pain, backache and leucorrhagia, there are totally effective rate 95.65%, 96.36%, 88.10%, compared with control group, there is obvious differential (P<0.01).
(2) The result of orthogonal design: Apply orthogonal design method of LI A (2 ) orthogonal table . The result show that herbal medicine A,B,D,E,F is mainly
factor in Fu Yan Jing mixture.
(3) The result of normal mechanism: The result of normal mechanism shows that Fu Yan Jing mixture can reduce mouse's inflammation of ear by dimethylbenzene, inhibit rat's granulose tissue growth by foreign body subject, reduce mouse's wriggle times by glacial acetic-acid, raise rat's threshold of pain, reduce mouse's abdominal blood capillary penetrating character by glacial acetic-acid.
(4) The result of monitors by MTT method shows that, Fu Yan Jing mixture can inhibit proliferation of rat's spleen cell, and inhibit NIH3T3 fibroblastic proliferation. Applying reverse transcriptase polymerase chain reaction (RT-PCR) technique monitor the expression of collagen type III mRNA , the result shows
that Fu YanJing mixture can inhibit the expression of collagen type III mRNA.
Conclusion: Clinical observing of Fu Yan Jing mixture show that, it's clinical effects on chronic pelvic inflammatory disease (CPID) is sure. Deeply research show that , Fu Yan Jing mixture can inhibit the expression of collagen type III mRNA and inhibit NIH3T3 fibroblastic proliferation. Explore that, it is one of the important mechanism for reducing chronic inflammatory pathomorphism. It embodies important factor of "Zhu Yu Qin Hua" method in treat chronic pelvic inflammatory disease (CPID).
盆腔炎，并创研妇炎净合剂。采用随机、对照法对妇炎净合剂治疗慢性盆腔
炎进行了临床疗效评价。使用L16(28) 表正交分析法对妇炎净合剂进行了拆
方分析，研究方中各药物的作用。经典方法对妇炎净合剂进行了一般药效学
及模型病理观察，观察了试验药对大鼠脾细胞、NIH3T3成纤维细胞增殖及Ⅲ
型胶原蛋白mRNA表达的影响，以探讨妇炎净合剂对脾细胞、成纤维细胞及
胶原转录基因的调节作用。通过以上实验研究，从整体、细胞、分子水平系
统分析了妇炎净合剂治疗慢性盆腔炎的机理。结果如下：
(1) 临床观察结果：采用随机、对照方法观察治疗180例慢性盆腔炎
患者，其中治疗组120例、对照组60例，结果显示，治疗组有效率96． 67％，
愈显率78． 33％，对照组有效率80％，愈显率34％，两组比较有显著性差异
(P＜0． 01) 。治疗组腹痛、腹坠胀、腰酸痛、带下主要症状的改善，优于对照
组，两组比较有显著性差异(P＜0． 01) 。
(2) 正交分析结果：采用L16(28) 正交表分析表明，妇炎净合剂方中
A、B、E、F、D药物是主要作用因素。
(3) 一般药效学研究结果：妇炎净合剂具有抑制二甲苯至小鼠耳肿胀，
抑制大鼠塑料环肉芽肿增生，减少小鼠冰醋酸所致扭体次数，提高大鼠痛阈，
降低小鼠冰醋酸所致腹腔毛细血管通透性的作用。
(4) MTT法检测显示：妇炎净合剂能抑制体外培养大鼠脾细胞、
NIH3T3成纤维细胞增生。RT-PCR方法检测结果：妇炎净合剂能抑制NIH3T3
成纤维细胞Ⅲ型胶原蛋白mRNA的表达。
结论妇炎净合剂是临床治疗慢性盆腔炎的有效药物。具有镇痛、减轻
渗出、减少局部增生、减轻盆腔病理改变的药理作用。深入研究表明，妇炎
净合剂可抑制成纤维细胞增生及其Ⅲ型胶原蛋白mRNA表达，分析该作用是
药物逆转慢性炎症局部病理改变的重要机制之一，体现了“逐瘀清化”法在
慢性盆腔炎治疗中的重要意义。
Objective: The subject systematicly treats chronic pelvic inflammatory disease (CPID) with "Zhu Yu Qing Hua" method based on better clinical effects in 30 years over, established "FU YAN JING" mixture. To observe and study clinical effects of chronic pelvic inflammatory disease (CPID) by Fu Yan Jing mixture, explore the mechanisms on improving chronic inflammatory pathology.
Method and Result: (1) In clinic, using method of random, contrast for observing and treating 180 cases of patients with chronic pelvic inflammatory disease (CPID), dividing them into 120 cases in treating group, 60 cases in controlling group. The results show that in total effects, there are totally effective rate 96.67% and cure rate and markedly effective rate 78.33%. Compared with control group, there is obvious differential (/><0.01). In the effects of clinical symptom such as abdominal pain, backache and leucorrhagia, there are totally effective rate 95.65%, 96.36%, 88.10%, compared with control group, there is obvious differential (P<0.01).
(2) The result of orthogonal design: Apply orthogonal design method of LI A (2 ) orthogonal table . The result show that herbal medicine A,B,D,E,F is mainly
factor in Fu Yan Jing mixture.
(3) The result of normal mechanism: The result of normal mechanism shows that Fu Yan Jing mixture can reduce mouse's inflammation of ear by dimethylbenzene, inhibit rat's granulose tissue growth by foreign body subject, reduce mouse's wriggle times by glacial acetic-acid, raise rat's threshold of pain, reduce mouse's abdominal blood capillary penetrating character by glacial acetic-acid.
(4) The result of monitors by MTT method shows that, Fu Yan Jing mixture can inhibit proliferation of rat's spleen cell, and inhibit NIH3T3 fibroblastic proliferation. Applying reverse transcriptase polymerase chain reaction (RT-PCR) technique monitor the expression of collagen type III mRNA , the result shows
that Fu YanJing mixture can inhibit the expression of collagen type III mRNA.
Conclusion: Clinical observing of Fu Yan Jing mixture show that, it's clinical effects on chronic pelvic inflammatory disease (CPID) is sure. Deeply research show that , Fu Yan Jing mixture can inhibit the expression of collagen type III mRNA and inhibit NIH3T3 fibroblastic proliferation. Explore that, it is one of the important mechanism for reducing chronic inflammatory pathomorphism. It embodies important factor of "Zhu Yu Qin Hua" method in treat chronic pelvic inflammatory disease (CPID).
引文
1． 王淑善．王少华用加味四妙汤治疗慢性盆腔炎经验．浙江中医杂志，2003； (3) ：407
2． 薛纪香．中西医结合治疗慢性盆腔炎128例临床观察．临床医药实践杂 志，2003：12(1) ：57
3． 潘鸿鹄著．中医药治疗炎症学．军事医学科学出版社
4． 王付．经方辨治慢性盆腔炎．四川中医，2003；21(6) ：21
5． 任晓丹．慢性盆腔炎辨治体会．实用中医药杂志，2002；18(6) ：40
6． 唐时静等．红藤化瘀汤治疗慢性盆腔炎136例．安徽中医学院学报，2002； 21(3) ：20
7． 张丽春等．活血化瘀解毒法配合中药灌肠治疗慢性盆腔炎100例。传统中医 药．2002；19(4) ：46
8． 尹梅兰．妇炎合剂治疗慢性盆腔炎200例．福建中医药，2002；33(4) ：33
9． 魏晓芬．薏苡附子败酱散合当归芍药散治疗慢性盆腔炎62例．四川中医， 2002：20(12) ：44
10． 章勤．何少山治疗盆腔炎的临床经验．浙江中医杂志，1998；33(2) ：75
11． 章勤等．芪竭颗粒治疗慢性盆腔炎102例临床观察．中医杂志，2003；44 (2) ：121
12． 张红云．中药保留灌肠治疗慢性盆腔炎36例临床观察．安徽中医学院学 报，1999；18(4) ：39
13． 邹丽红，等．灌肠治疗慢性盆腔炎36例临床观察．吉林中医药，2000；20 (6) ：2528
14． 王肖凤．中药肛肠点滴治疗慢性盆腔炎100例．中国中医药科技，1997； (4) ：283
15． 闫俊英，等．小金丹敷脐治疗慢性盆腔炎50例．陕西中医，2003；24(11) ：972
16． 王艳兰．沙蒿子散外敷治疗慢性盆腔炎52例疗效观察．中医外治杂 志，2002；11(6) ：13
17． 范激明，等．中药内服配合灌肠治疗慢性盆腔炎．河南中医，2003；23(2) ：31
18． 汤永华．综合治疗慢性盆腔炎50例疗效观察．现代中西医结合杂 志，2003；12(6) ：590
19． Lakic P, Mcculloch CA. Periodontal ligament cell populations :The central role of fibroblasts in creating a unique tissue. Anat Rec, 1996;245(2) :327
20． Kingsnorth AN, Slavin J. Peptide growth factors and wound healing. J Surg(Br),1991;78(11) :1286
21． Tuan TL, Song S,Chang S, et al. In vitro fibroblasia: Matrix contraction, cell growth, and collagen production of fibroblasts cultured in fibrin gels. Exp Cell Res, 1996;223(1) :127
22． Longaker M, Whitby D, Adzick NS, et al. Studies in fetal wound healing Ⅵ.J Pedis Sutg,1990:25:63-68
23． Decker M,Chiu ES, Dollaum C,et al.A hyaluronic acid stimulating factor from the bovine fetus and from breast cancer patients Cancer Res,1989,3499-3504
24． Victoria M,Asteria A,Louis M,,et al. Wound healing in the fetal period: the resistance of the scar tupture. J Pedia Sutg, 1993:28:1458-1462
25． Dgnass AU,Tsunekawa S, Podoslky DK.Fibroblast growth factors modulate intestinal epithelial cell growth and migration.Gastroenterology, 1994, 106:1254-1262
26． Srivastava AK, Use of phamacological Srivastava AK. Use of pharmacological agents in elucidating the mechanism of insulin action [J] . Trends Pharmacol Sci, 1998,19:205．
27． Kunkel SL, Lukacs N, Kasama T, et al. The role of chemokines in inflammatory joint disease [J] . J Leukocyte Biol, 1996, 59: 6．
28． Sakuta T, Tokuda M, Tamura M, et al. Dual regulatory effects of interferon-alpha,-beta, and-gamma on interleukin-8 gene expression by human gingival fibroblasts in culture upon
stimulation with lipopolysaccharide from prevotella intermedia, interleukin-1 alpha, or tumor necrosis factor-alpha [J] . J Dent Res, 1998 ,77:1597．
29． Mino T, Sugiyama E, Taki H. Interleukin-1 alpha and tumor necrosis factor alpha synergistically stimulate prostaglandin E2-dependent production of interleukin-11 in rheumatoid synovial fibroblasts [J].Arthritis Rheum, 1998,41:2004．
30． Wang HS, Cao HJ, Winn VD, et al. Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts: an in vitro model for connective tissue inflammation [J] . J Biol Chem, 1996,27: 22718．
31． 杨永平，宋喜秀，等．软肝片对中毒性肝纤维化大鼠的影响．中西医结合肝 病杂志1994；4(3) ：22-24
32． 熊磊．三七治疗肝病的实验研究进展．中草药1998；29(8) ：567-568
33． 韦颖，等．三七总甙对人肾成纤维细胞的影响．中国中西医结合杂 志．2002，22(1) ：47
34． 董莉，李斌，等．生肌化瘀方及其拆方对大鼠创面成纤维细胞Ⅰ、Ⅲ型胶 原合成的影响．中国中西医结合杂志2002；22(3) ：200
35． 魏恩会，等．Ⅰ型胶原对巨噬细胞提取氧化低密度脂蛋白的作用．生物化学 与生物物理学报，1997，29(5) ：443-448
36． 刘明友，等．血清牛Ⅲ型胶原含量与肝维纤化的关系．中华核医学杂 志，1995，15(3) ：132-134
37． 蔡国平，等．胶原蛋白的电子活化与矽肺纤维化Ⅰ．生物物理学 报，1991，7(2) ：239-243
38． 史景熙，等．胶原蛋白的电子活化与矽肺纤维化Ⅱ．生物物理学 报，1991，7(3) ：295-299
39． 李书忠，等．椎间盘胶原分布的研究．中华骨科杂志，1992，12(3) ：213-217
40． 张选奋，等．银屑病皮损和正常人皮肤五种细胞外基质成份免疫组化检测． 中华皮肤科杂志，1995，28(2) ：83-85
41． 侯建新，等．层粘连蛋白和Ⅳ型胶原在皮肤恶性黑色素瘤及痣细胞疾病中 的表达．中华皮肤科杂志，1997，30(6) ：396-397
42． 马晓丽，等．牛Ⅲ型前胶原的提取及抗血清的制备．生物化学杂 志，1987，3(4) ：377
43． Burkard Gerling. Elevated serum aminoterminal procollagen type-Ⅲ-peptid parallels collagen accumulation in rats with secondary billiary fibrosis . Journal of Hepatology 1996,25:79-84
44． Tourkin, A., Anderson, T., et al. Eosinophil adhesion and maturation is modulated by laminin adhesion and maturation is modulatedby laminin.Cell Adhes . Commun 1993, (1) :161-176
45． Leonard, A. , Abatangelo, G. , et al. Collagen types Ⅰ and Ⅲ in giant papillae of vernal kerotoconjunctivitis . Br. J. Ophthalmol 1995,79:482-485
46． Gabriel GB, Corroocher R. Hepatie fibrosis and its serum markers;a review. Dig Dis 1991,9:303-16
47． Atlanta, Ga. Davison of STD/HIV prevention Ammual Report, 1989． Centers for Disease Control, 1989．
48． Yeh JM, Hook EW 3rd, Goldie SJ. A refined estimate of the average lifetime cost of pelvic inflammatory disease. Sex Transm Dis. 2003 May;30(3) :369-78．
49． Hemdor DN, Barrow RE, Kunkel KP, et al. Regulation of fibroplasias in coelaneous wound repair. Ann Surg 1990:212(4) :424-429
50． Hirschel BJ, Ryam GB, Kunkel KP,et al. Granulation lissue as contractile organ. Ann Surg 1990;212(4) :424-429
51． 实用妇产科病理学．黄志勇主编．江苏科学技术出版社
52． Burbul. Immune aspects of wound healing. Clin Plast Surg, 1990, 17(2) : 433-438
53． Liu B,Connolly MK. The pathogenesis of cutaneous fibrosis. Semin Cutsn Med Sutg,1998;17:3-11
54． Hemdor DN, Barrow RE, Kunkel KP, et al. Regulation of fibroplasias in coelaneous wound repair. Ann Surg 1990;212(4) :424-429
55． Ching T. Molecular cloning of the complemenlary DNA encoding for the hamsler TGF-α mature peptide. Carcinogenesis 1991;12:529
56． Hirschel BJ, Ryam GB, Kunkel KP,et al. Granulation lissue as contractile organ. Ann Surg 1990;212(4) :424-429
57． 宛建新，等．成纤维细胞活性变化与食管支架术后再狭窄的相关性研究．中 华消化杂志，2003；23(3) ：3
58． 耿智敏，等．犬胆肠吻合愈合过程的组织学观察．西安医科大学学 报．2000，21(5) ：447
59． 刘阳，等．翼状胬肉组织病理学研究及相关因子的检测．眼 科，2000；9(6) ：357
60． Young D, Lathigra R,Hendrix R, et al. Stress proteins are immune targets is leprosy and tuberculosis . Procnatl 1981;143:41
61． Densen P, Gulatis, R ice PA, Specifcity of antibodies against Neisseria gonorrhoeae that stimulate neutrophit chemotaxis J Clin Invest 1987;80:78
62． Rank RG. Sander MM. Kidd AT. Influence of the estrous cycle on the development of upper genital tract pathology as a result of chlamydial infection in the guinea pelvic inflammatory disease. Am J Pathol. 1993;142(4) : 1291-1296
63． Morrison SG, Morrison RP. In situ analysis of the evolution of the primary immune response in murine Chlamydia trachomatis genital tract infection[J] . Infect Immun, 2000, 68(3) :2870-2879．
64． Morrison SG, Su H, Caldwell HD, et al. Immuruty to murine chlamydial trachomatis genital tract reinfection involves B cells and CD4+ T cells but not CD8+ T cells[J]. Infect Immrn, 2000, 68(2) ;6979-6987
65． Wyrick PB, Knight ST, Paul TR, et al. Persistent chlamydial envelope antigens in antibiotic-exposed infected cells trigger neutrophil
chemotaxis. J Infect Dis . 1999;179:954-966
66． Tseng CK,Rank RG, Role of NK cells in early bost response to chlamydial genital infection. Infect Immun., 1989:66:57867-57875
67． Ito JI . Role of gamma interferon in controlling murinc chlamydial genital tract infection . Infect Immun, 1999;67(10) :5518-5521
68． Morrison SG, Morrison RP. In situ analysis of the evolution of the primary immune response in murine Chlamydia trachomatis genital tract infection . Infect Immun, 2000, 68(5) ;2870-2879
69． Patton DL , Landers DV, Sternfield MD , et al . Expertmental Chlamydia trachomatis salpingitis inmice. intialstudies on the eharaeterization of the leukocyte response to Chlamydia infection . J Infect Dis,1989;159:1105
70． Yi YS. Yang X. Brunham RC. et al. Antoimmunity to hsp60 and antigen-specific production of IL-10． Infect Immun. 1997, 63(3) ;1669-1674
71． Lavenda D , Albanese LN , Ruther PE, Seroreactivity to chlamydial trachomatis Hsp10 correlates with severity of Imman genital tract disease . Infect Immun 2000;68(1) :256-259
2． 薛纪香．中西医结合治疗慢性盆腔炎128例临床观察．临床医药实践杂 志，2003：12(1) ：57
3． 潘鸿鹄著．中医药治疗炎症学．军事医学科学出版社
4． 王付．经方辨治慢性盆腔炎．四川中医，2003；21(6) ：21
5． 任晓丹．慢性盆腔炎辨治体会．实用中医药杂志，2002；18(6) ：40
6． 唐时静等．红藤化瘀汤治疗慢性盆腔炎136例．安徽中医学院学报，2002； 21(3) ：20
7． 张丽春等．活血化瘀解毒法配合中药灌肠治疗慢性盆腔炎100例。传统中医 药．2002；19(4) ：46
8． 尹梅兰．妇炎合剂治疗慢性盆腔炎200例．福建中医药，2002；33(4) ：33
9． 魏晓芬．薏苡附子败酱散合当归芍药散治疗慢性盆腔炎62例．四川中医， 2002：20(12) ：44
10． 章勤．何少山治疗盆腔炎的临床经验．浙江中医杂志，1998；33(2) ：75
11． 章勤等．芪竭颗粒治疗慢性盆腔炎102例临床观察．中医杂志，2003；44 (2) ：121
12． 张红云．中药保留灌肠治疗慢性盆腔炎36例临床观察．安徽中医学院学 报，1999；18(4) ：39
13． 邹丽红，等．灌肠治疗慢性盆腔炎36例临床观察．吉林中医药，2000；20 (6) ：2528
14． 王肖凤．中药肛肠点滴治疗慢性盆腔炎100例．中国中医药科技，1997； (4) ：283
15． 闫俊英，等．小金丹敷脐治疗慢性盆腔炎50例．陕西中医，2003；24(11) ：972
16． 王艳兰．沙蒿子散外敷治疗慢性盆腔炎52例疗效观察．中医外治杂 志，2002；11(6) ：13
17． 范激明，等．中药内服配合灌肠治疗慢性盆腔炎．河南中医，2003；23(2) ：31
18． 汤永华．综合治疗慢性盆腔炎50例疗效观察．现代中西医结合杂 志，2003；12(6) ：590
19． Lakic P, Mcculloch CA. Periodontal ligament cell populations :The central role of fibroblasts in creating a unique tissue. Anat Rec, 1996;245(2) :327
20． Kingsnorth AN, Slavin J. Peptide growth factors and wound healing. J Surg(Br),1991;78(11) :1286
21． Tuan TL, Song S,Chang S, et al. In vitro fibroblasia: Matrix contraction, cell growth, and collagen production of fibroblasts cultured in fibrin gels. Exp Cell Res, 1996;223(1) :127
22． Longaker M, Whitby D, Adzick NS, et al. Studies in fetal wound healing Ⅵ.J Pedis Sutg,1990:25:63-68
23． Decker M,Chiu ES, Dollaum C,et al.A hyaluronic acid stimulating factor from the bovine fetus and from breast cancer patients Cancer Res,1989,3499-3504
24． Victoria M,Asteria A,Louis M,,et al. Wound healing in the fetal period: the resistance of the scar tupture. J Pedia Sutg, 1993:28:1458-1462
25． Dgnass AU,Tsunekawa S, Podoslky DK.Fibroblast growth factors modulate intestinal epithelial cell growth and migration.Gastroenterology, 1994, 106:1254-1262
26． Srivastava AK, Use of phamacological Srivastava AK. Use of pharmacological agents in elucidating the mechanism of insulin action [J] . Trends Pharmacol Sci, 1998,19:205．
27． Kunkel SL, Lukacs N, Kasama T, et al. The role of chemokines in inflammatory joint disease [J] . J Leukocyte Biol, 1996, 59: 6．
28． Sakuta T, Tokuda M, Tamura M, et al. Dual regulatory effects of interferon-alpha,-beta, and-gamma on interleukin-8 gene expression by human gingival fibroblasts in culture upon
stimulation with lipopolysaccharide from prevotella intermedia, interleukin-1 alpha, or tumor necrosis factor-alpha [J] . J Dent Res, 1998 ,77:1597．
29． Mino T, Sugiyama E, Taki H. Interleukin-1 alpha and tumor necrosis factor alpha synergistically stimulate prostaglandin E2-dependent production of interleukin-11 in rheumatoid synovial fibroblasts [J].Arthritis Rheum, 1998,41:2004．
30． Wang HS, Cao HJ, Winn VD, et al. Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts: an in vitro model for connective tissue inflammation [J] . J Biol Chem, 1996,27: 22718．
31． 杨永平，宋喜秀，等．软肝片对中毒性肝纤维化大鼠的影响．中西医结合肝 病杂志1994；4(3) ：22-24
32． 熊磊．三七治疗肝病的实验研究进展．中草药1998；29(8) ：567-568
33． 韦颖，等．三七总甙对人肾成纤维细胞的影响．中国中西医结合杂 志．2002，22(1) ：47
34． 董莉，李斌，等．生肌化瘀方及其拆方对大鼠创面成纤维细胞Ⅰ、Ⅲ型胶 原合成的影响．中国中西医结合杂志2002；22(3) ：200
35． 魏恩会，等．Ⅰ型胶原对巨噬细胞提取氧化低密度脂蛋白的作用．生物化学 与生物物理学报，1997，29(5) ：443-448
36． 刘明友，等．血清牛Ⅲ型胶原含量与肝维纤化的关系．中华核医学杂 志，1995，15(3) ：132-134
37． 蔡国平，等．胶原蛋白的电子活化与矽肺纤维化Ⅰ．生物物理学 报，1991，7(2) ：239-243
38． 史景熙，等．胶原蛋白的电子活化与矽肺纤维化Ⅱ．生物物理学 报，1991，7(3) ：295-299
39． 李书忠，等．椎间盘胶原分布的研究．中华骨科杂志，1992，12(3) ：213-217
40． 张选奋，等．银屑病皮损和正常人皮肤五种细胞外基质成份免疫组化检测． 中华皮肤科杂志，1995，28(2) ：83-85
41． 侯建新，等．层粘连蛋白和Ⅳ型胶原在皮肤恶性黑色素瘤及痣细胞疾病中 的表达．中华皮肤科杂志，1997，30(6) ：396-397
42． 马晓丽，等．牛Ⅲ型前胶原的提取及抗血清的制备．生物化学杂 志，1987，3(4) ：377
43． Burkard Gerling. Elevated serum aminoterminal procollagen type-Ⅲ-peptid parallels collagen accumulation in rats with secondary billiary fibrosis . Journal of Hepatology 1996,25:79-84
44． Tourkin, A., Anderson, T., et al. Eosinophil adhesion and maturation is modulated by laminin adhesion and maturation is modulatedby laminin.Cell Adhes . Commun 1993, (1) :161-176
45． Leonard, A. , Abatangelo, G. , et al. Collagen types Ⅰ and Ⅲ in giant papillae of vernal kerotoconjunctivitis . Br. J. Ophthalmol 1995,79:482-485
46． Gabriel GB, Corroocher R. Hepatie fibrosis and its serum markers;a review. Dig Dis 1991,9:303-16
47． Atlanta, Ga. Davison of STD/HIV prevention Ammual Report, 1989． Centers for Disease Control, 1989．
48． Yeh JM, Hook EW 3rd, Goldie SJ. A refined estimate of the average lifetime cost of pelvic inflammatory disease. Sex Transm Dis. 2003 May;30(3) :369-78．
49． Hemdor DN, Barrow RE, Kunkel KP, et al. Regulation of fibroplasias in coelaneous wound repair. Ann Surg 1990:212(4) :424-429
50． Hirschel BJ, Ryam GB, Kunkel KP,et al. Granulation lissue as contractile organ. Ann Surg 1990;212(4) :424-429
51． 实用妇产科病理学．黄志勇主编．江苏科学技术出版社
52． Burbul. Immune aspects of wound healing. Clin Plast Surg, 1990, 17(2) : 433-438
53． Liu B,Connolly MK. The pathogenesis of cutaneous fibrosis. Semin Cutsn Med Sutg,1998;17:3-11
54． Hemdor DN, Barrow RE, Kunkel KP, et al. Regulation of fibroplasias in coelaneous wound repair. Ann Surg 1990;212(4) :424-429
55． Ching T. Molecular cloning of the complemenlary DNA encoding for the hamsler TGF-α mature peptide. Carcinogenesis 1991;12:529
56． Hirschel BJ, Ryam GB, Kunkel KP,et al. Granulation lissue as contractile organ. Ann Surg 1990;212(4) :424-429
57． 宛建新，等．成纤维细胞活性变化与食管支架术后再狭窄的相关性研究．中 华消化杂志，2003；23(3) ：3
58． 耿智敏，等．犬胆肠吻合愈合过程的组织学观察．西安医科大学学 报．2000，21(5) ：447
59． 刘阳，等．翼状胬肉组织病理学研究及相关因子的检测．眼 科，2000；9(6) ：357
60． Young D, Lathigra R,Hendrix R, et al. Stress proteins are immune targets is leprosy and tuberculosis . Procnatl 1981;143:41
61． Densen P, Gulatis, R ice PA, Specifcity of antibodies against Neisseria gonorrhoeae that stimulate neutrophit chemotaxis J Clin Invest 1987;80:78
62． Rank RG. Sander MM. Kidd AT. Influence of the estrous cycle on the development of upper genital tract pathology as a result of chlamydial infection in the guinea pelvic inflammatory disease. Am J Pathol. 1993;142(4) : 1291-1296
63． Morrison SG, Morrison RP. In situ analysis of the evolution of the primary immune response in murine Chlamydia trachomatis genital tract infection[J] . Infect Immun, 2000, 68(3) :2870-2879．
64． Morrison SG, Su H, Caldwell HD, et al. Immuruty to murine chlamydial trachomatis genital tract reinfection involves B cells and CD4+ T cells but not CD8+ T cells[J]. Infect Immrn, 2000, 68(2) ;6979-6987
65． Wyrick PB, Knight ST, Paul TR, et al. Persistent chlamydial envelope antigens in antibiotic-exposed infected cells trigger neutrophil
chemotaxis. J Infect Dis . 1999;179:954-966
66． Tseng CK,Rank RG, Role of NK cells in early bost response to chlamydial genital infection. Infect Immun., 1989:66:57867-57875
67． Ito JI . Role of gamma interferon in controlling murinc chlamydial genital tract infection . Infect Immun, 1999;67(10) :5518-5521
68． Morrison SG, Morrison RP. In situ analysis of the evolution of the primary immune response in murine Chlamydia trachomatis genital tract infection . Infect Immun, 2000, 68(5) ;2870-2879
69． Patton DL , Landers DV, Sternfield MD , et al . Expertmental Chlamydia trachomatis salpingitis inmice. intialstudies on the eharaeterization of the leukocyte response to Chlamydia infection . J Infect Dis,1989;159:1105
70． Yi YS. Yang X. Brunham RC. et al. Antoimmunity to hsp60 and antigen-specific production of IL-10． Infect Immun. 1997, 63(3) ;1669-1674
71． Lavenda D , Albanese LN , Ruther PE, Seroreactivity to chlamydial trachomatis Hsp10 correlates with severity of Imman genital tract disease . Infect Immun 2000;68(1) :256-259